Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial
Abstract
Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate higher doses of GDMT. Using the HF-ACTION trial, we examined (1) the relationship between BSA and achievement of target dosing of evidence-based beta-blocker and angiotensin-converting enzyme...
Paper Details
Title
Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial
Published Date
Mar 1, 2021
Journal
Volume
233
Pages
1 - 4
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History